Sep 16 |
AstraZeneca Imfinzi + Imjudo combo shows long-term liver cancer survival benefit
|
Sep 16 |
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial
|
Sep 16 |
AstraZeneca's Trial Shows IMFINZI Reduces Risk of Recurrence, Death in Patients With Bladder Cancer
|
Sep 16 |
ASCO 2020: ADAURA trial demonstrates a 79% reduction in the risk of death with Tagrisso in the adjuvant setting
|
Sep 15 |
IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial
|
Sep 13 |
AstraZeneca, Daiichi Sankyo Breast Cancer Drug Trial Shows 'Substantial Clinical Activity'
|
Sep 13 |
AstraZeneca, Roche cut at Deutsche after trial readouts for key drugs
|
Sep 13 |
ENHERTU® (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases
|
Sep 13 |
AstraZeneca Shares Set For Worst Week in 14 Months on Sell Calls
|
Sep 12 |
AstraZeneca: Dato-DXd Should Still Be Approved In Q4 Despite Underwhelming Data
|